KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Ionis Pharmaceuticals (IONS) EBIT Margin (2016 - 2025)

Historic EBIT Margin for Ionis Pharmaceuticals (IONS) over the last 17 years, with Q3 2025 value amounting to 102.21%.

  • Ionis Pharmaceuticals' EBIT Margin rose 88800.0% to 102.21% in Q3 2025 from the same period last year, while for Sep 2025 it was 35.07%, marking a year-over-year increase of 110500.0%. This contributed to the annual value of 67.37% for FY2024, which is 224600.0% down from last year.
  • Per Ionis Pharmaceuticals' latest filing, its EBIT Margin stood at 102.21% for Q3 2025, which was up 88800.0% from 50.29% recorded in Q2 2025.
  • Ionis Pharmaceuticals' EBIT Margin's 5-year high stood at 50.29% during Q2 2025, with a 5-year trough of 136.95% in Q4 2022.
  • Its 5-year average for EBIT Margin is 60.41%, with a median of 63.92% in 2022.
  • Its EBIT Margin has fluctuated over the past 5 years, first surged by 3400800bps in 2021, then plummeted by -1870900bps in 2022.
  • Ionis Pharmaceuticals' EBIT Margin (Quarter) stood at 50.14% in 2021, then crashed by -373bps to 136.95% in 2022, then soared by 99bps to 1.89% in 2023, then tumbled by -2493bps to 48.91% in 2024, then plummeted by -109bps to 102.21% in 2025.
  • Its EBIT Margin was 102.21% in Q3 2025, compared to 50.29% in Q2 2025 and 111.59% in Q1 2025.